Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Clinical trial NCT00254423 · COMPLETED

Trial details

NCT number: NCT00254423
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Start date: 2005-11-08
Primary completion: 2025-03-14
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.